B细胞淋巴瘤/白血病-2基因与核内原癌基因的mRNA联合检测诊断乳腺癌的临床研究

目的探讨联合检测B细胞淋巴瘤/白血病-2基因(B cell lymphoma/leukemia 2 gene,BCL-2)与核内原癌基因(Nuclear oncogene,myc)基因表达水平在乳腺癌诊断和治疗监测中的应用。方法建立荧光定量聚合酶链反应(FQ-PCR)法,并以β2-微球蛋白为内对照测定15名健康女性体检者(正常对照组)、30例良性乳腺疾病患者(良性乳腺疾病组)和140例乳腺癌患者(乳腺癌组)外周血中BCL-2和myc的表达量。结果 BCL-2和myc表达水平与β2-微球蛋白的比值在健康女性体检者、良性乳腺疾病和乳腺癌患者分别为(1.32±0.12)×10-3,(1.31±0.11)×10-3,(6.36±1.02)×10-3,(1.14±0.07)×10-3,(1.15±0.06×)10-3,(2.77±1.41)×10-3,在正常对照组和良性乳腺疾病组间差异无统计学意义(P>0.05),乳腺癌组均高于前两组(P<0.05),3组β2-微球蛋白差异无统计学意义(P>0.05);BCL-2与myc联合检测的灵敏度高于单个基因的检测。结论 FQ-PCR技术可以快速定量检测BCL-2和myc mRNA,两者联合检测可有效提高对乳腺癌诊断的灵敏度。

Clinical study on B-cell lymphoma/leukemia-2 and myc gene mRNA in the diagnosis of breast cancer

Objective To evaluate the combined application of BCL-2 and myc gene expression in the diagnosis of breast cancer.Methods The expression of BCL-2 and myc were detected by FQ-PCR 15 health women,30 patients with benign breast disease and 140 patients with breast cancer.β₂-microglobin was used as internal control. Results The ratio of BCL-2 and myc divided by β₂-microglobin in health women,patients with benign breast disease and patients with breast cancer were（1.32±0.12）×10-3,（1.31±0.11）×10-3,（6.36±1.02）×10-3,（1.14±0.07）×10-3,（1.15±0.06）×10-3,and（2.77±1.41）×10-3.There was no significant difference between normal controls and patients with benign breast disease（P > 0.05）.The ratio of BCL-2 and myc divided by β₂-microglobin in patients with breast cancer was higher than that in the other groups（P < 0.05）.There was no difference in β₂-microglobin among three groups（P > 0.05）.The sensitivity of BCL-2 and myc gene expression by the combined detection was higher than that by single gene detection. Conclusions FQ-PCR is a rapid method for quantitating BCL-2 and myc.The combined detection can improve the sensitivity of diagnosis in breast cancer.